PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
121.05%
Some net income increase while CRVO is negative at -222.80%. John Neff would see a short-term edge over the struggling competitor.
473.10%
D&A growth well above CRVO's 69.21%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
20.60%
Deferred tax of 20.60% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-20.60%
Both cut yoy SBC, with CRVO at -5.72%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
534.15%
Slight usage while CRVO is negative at -623.38%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.02%
A yoy AP increase while CRVO is negative at -1148.32%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
107.35%
Some yoy usage while CRVO is negative at -38.92%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-145.76%
Negative yoy while CRVO is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-3.22%
Both yoy CFO lines are negative, with CRVO at -982.99%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-7359.68%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
-7359.68%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
37.62%
We repay more while CRVO is negative at -100.00%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
299.00%
Issuance growth of 299.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.